|

68Ga-XHER2 PET/CT for HER2 Assessment

RECRUITINGN/ASponsored by The First Affiliated Hospital of Xiamen University
Actively Recruiting
PhaseN/A
SponsorThe First Affiliated Hospital of Xiamen University
Started2026-10-22
Est. completion2027-10-22
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The objective of this study is to evaluate the feasibility of 68Ga-XHER2 PET/CT as a noninvasive imaging approach for assessing HER2 expression in patients with solid tumors and to investigate the correlation between tracer uptake and pathological HER2 expression.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* adult patients (aged 18 years or older)
* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
* patients who had scheduled both standard-of-care imaging and 68Ga-XHER2 PET/CT scans
* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee

Exclusion Criteria:

* patients with pregnancy
* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent

Conditions4

CancerHER2PET-CTSolid Tumor (Excluding CNS)

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.